人肺腺癌細(xì)胞PC-9

簡(jiǎn)要描述：青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺(tái)，在標(biāo)準(zhǔn)化細(xì)胞庫(kù)建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營(yíng)原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測(cè)等科研產(chǎn)品與服務(wù)。我們秉承對(duì)用戶(hù)負(fù)責(zé)的態(tài)度，以對(duì)科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶(hù)提供更優(yōu)質(zhì)的服務(wù)！

更新時(shí)間：2021-05-24

廠商性質(zhì)：生產(chǎn)廠家

瀏覽次數(shù)：448

留言詢(xún)價(jià)聯(lián)系我們

詳情介紹

品牌	其他品牌	貨號(hào)	BFN60800699
規(guī)格	T25培養(yǎng)瓶x1 1.5ml凍存管x2	供貨周期	現(xiàn)貨
主要用途	僅供科研	應(yīng)用領(lǐng)域	醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

細(xì)胞名稱(chēng)	人肺腺癌細(xì)胞PC-9
貨物編碼	BFN60800699
產(chǎn)品規(guī)格	T25培養(yǎng)瓶x1	1.5ml凍存管x2
細(xì)胞數(shù)量	1x10^6	1x10^6
保存溫度	37℃	-198℃
運(yùn)輸方式	常溫保溫運(yùn)輸	干冰運(yùn)輸
安全等級(jí)	1
用途限制	僅供科研用途 1類(lèi)

培養(yǎng)體系	DMEM高糖培養(yǎng)基（Hyclone）+10%胎牛血清（Gibco）+1%雙抗（Hyclone）
培養(yǎng)溫度	37℃	二氧化碳濃度	5%
簡(jiǎn)介	人肺腺癌細(xì)胞PC-9 于1989年取自一位日本人肺癌組織。
注釋	Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: MD Anderson Cell Lines Project. From: Immuno-Biological Laboratories (IBL); Tokyo; Japan. Omics: Deep exome analysis. Omics: Deep membrane proteome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep RNAseq analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis.
STR信息	Amelogenin X CSF1PO 11 D2S1338 19,20 D3S1358 16 D5S818 11 D7S820 10,11 D8S1179 11,15 D13S317 8 D16S539 9 D18S51 15 D19S433 13,15.2 D21S11 30 FGA 23 Penta D 13 Penta E 11 TH01 7 TPOX 11 vWA 17
參考文獻(xiàn)	DOI=10.5795scc.24.451 Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y., Higuchi H., Uei Y. Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma. Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985) PubMed=4094096 Lee Y.-C., Saijo N., Sasaki Y., Takahashi H., Sakurai M., Ishihara J., Hoshi A., Chen K.-M., Hamburger A.W. Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay. Jpn. J. Clin. Oncol. 15:637-644(1985) PubMed=1847845; DOI=10.1007/BF00685110 Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T., Saijo N. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother. Pharmacol. 27:263-270(1991) PubMed=1737336 Yoshino I., Yano T., Murata M., Ishida T., Sugimachi K., Kimura G., Nomoto K. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res. 52:775-781(1992) PubMed=9023415; DOI=10.1006/cimm.1996.1062 Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. Cell. Immunol. 175:101-110(1997) PubMed=9178645; DOI=10.1006/cimm.1997.1108 Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K. CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma. Cell. Immunol. 177:176-181(1997) PubMed=11005564; DOI=10.1038/sj.neo.7900094 Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J. Mutation and expression of the DCC gene in human lung cancer. Neoplasia 2:300-305(2000) PubMed=11078804; DOI=10.3892/ijo.17.6.1187 Takenaka K., Shibuya M., Takeda Y., Hibino S., Gemma A., Ono Y., Kudoh S. Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int. J. Oncol. 17:1187-1194(2000) PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331 Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276-7282(2005) PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339 Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 67:2046-2053(2007) PubMed=17511773; DOI=10.1111/j.1349-7006.2007.00507.x Fukuyama T., Ichiki Y., Yamada S., Shigematsu Y., Baba T., Nagata Y., Mizukami M., Sugaya M., Takenoyama M., Hanagiri T., Sugio K., Yasumoto K. Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci. 98:1048-1054(2007) PubMed=19472407; DOI=10.1002/humu.21028 Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M. A gene-alteration profile of human lung cancer cell lines. Hum. Mutat. 30:1199-1206(2009) PubMed=19799608; DOI=10.1111/j.1349-7006.2009.01351.x Kuroda K., Takenoyama M., Baba T., Shigematsu Y., Shiota H., Ichiki Y., Yasuda M., Uramoto H., Hanagiri T., Yasumoto K. Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma. Cancer Sci. 101:46-53(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010) PubMed=22313637; DOI=10.4161/cbt.19238 Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. Cancer Biol. Ther. 13:369-378(2012) PubMed=23733853; DOI=10.1101/gr.152322.112 Jia P., Jin H., Meador C.B., Xia J., Ohashi K., Liu L., Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z., Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res. 23:1434-1445(2013) PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477 Kitata R.B., Dimayacyac-Esleta B.R., Choong W.-K., Tsai C.-F., Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D., Nesvizhskii A.I., Sung T.-Y., Chen Y.-J. Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry. J. Proteome Res. 14:3658-3669(2015) PubMed=26554430; DOI=10.1021/acs.analchem.5b03639 Dimayacyac-Esleta B.R., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J. Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling. Anal. Chem. 87:12016-12023(2015) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017) PubMed=28290473; DOI=10.1038ep44021 Wang Y.-T., Pan S.-H., Tsai C.-F., Kuo T.-C., Hsu Y.-L., Yen H.-Y., Choong W.-K., Wu H.-Y., Liao Y.-C., Hong T.-M., Sung T.-Y., Yang P.-C., Chen Y.-J. Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant target in non-small cell lung cancer. Sci. Rep. 7:44021-44021(2017) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)

驗(yàn)收細(xì)胞注意事項(xiàng)

1、收到人肺腺癌細(xì)胞PC-9細(xì)胞，請(qǐng)查看瓶子是否有破裂，培養(yǎng)基是否漏出，是否渾濁，如有請(qǐng)盡快聯(lián)系。

2、收到人肺腺癌細(xì)胞PC-9細(xì)胞，如包裝完好，請(qǐng)?jiān)陲@微鏡下觀察細(xì)胞。,由于運(yùn)輸過(guò)程中的問(wèn)題，細(xì)胞培養(yǎng)瓶中的貼壁細(xì)胞有可能從瓶壁中脫落下來(lái)，顯微鏡下觀察會(huì)出現(xiàn)細(xì)胞懸浮的情況，出現(xiàn)此狀態(tài)時(shí)，請(qǐng)不要打開(kāi)細(xì)胞培養(yǎng)瓶，應(yīng)立即將培養(yǎng)瓶置于細(xì)胞培養(yǎng)箱里靜止 3-5 小時(shí)左右，讓細(xì)胞先穩(wěn)定下，再于顯微鏡下觀察，此時(shí)多數(shù)細(xì)胞會(huì)重新貼附于瓶壁。如細(xì)胞仍不能貼壁，請(qǐng)用臺(tái)盼藍(lán)染色法鑒定細(xì)胞活力，如臺(tái)盼藍(lán)染色證實(shí)細(xì)胞活力正常請(qǐng)按懸浮細(xì)胞的方法處理。

3、收到人肺腺癌細(xì)胞PC-9細(xì)胞后，請(qǐng)鏡下觀察細(xì)胞，用恰當(dāng)方式處理細(xì)胞。若懸浮的細(xì)胞較多，請(qǐng)離心收集細(xì)胞，接種到一個(gè)新的培養(yǎng)瓶中。棄掉原液，使用新鮮配制的培養(yǎng)基，使用進(jìn)口胎牛血清。剛接到細(xì)胞，若細(xì)胞不多時(shí) 血清濃度可以加到 15％去培養(yǎng)。若細(xì)胞迏到 80%左右，血清濃度還是在 10％。

4、收到人肺腺癌細(xì)胞PC-9細(xì)胞時(shí)如無(wú)異常情況，請(qǐng)?jiān)陲@微鏡下觀察細(xì)胞密度，如為貼壁細(xì)胞，未超過(guò)80%匯合度時(shí)，將培養(yǎng)瓶中培養(yǎng)基吸出，留下 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng)：超過(guò) 80%匯合度時(shí)，請(qǐng)按細(xì)胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細(xì)胞，吸出培養(yǎng)液，1000 轉(zhuǎn)/分鐘離心 3 分鐘，吸出上清，管底細(xì)胞用新鮮培養(yǎng)基懸浮細(xì)胞后移回培養(yǎng)瓶。

5、將培養(yǎng)瓶置于 37℃培養(yǎng)箱中培養(yǎng)，蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過(guò)的瓶子里，存放于 4℃冰箱，以備不時(shí)之需。

6、24 小時(shí)后，人肺腺癌細(xì)胞PC-9細(xì)胞形態(tài)已恢復(fù)并貼滿瓶壁，即可傳代。（貼壁細(xì)胞）將培養(yǎng)瓶里的培養(yǎng)基倒去，加 3-5ml（以能覆蓋細(xì)胞生長(zhǎng)面為準(zhǔn)）PBS 或 Hanks’液洗滌后棄去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化時(shí)間以具體細(xì)胞為準(zhǔn)，一般 1-3 分鐘，不超過(guò) 5 分鐘?？梢苑?/span>入37℃培養(yǎng)箱消化。輕輕晃動(dòng)瓶壁，見(jiàn)細(xì)胞脫落下來(lái)，加入 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細(xì)胞，使之*脫落，然后將溶液吸入離心管內(nèi)離心，1000rpm/5min。棄上清，視細(xì)胞數(shù)量決定分瓶數(shù)，一般一傳二，如細(xì)胞量多可一傳三，有些細(xì)胞不易傳得過(guò)稀，有些生長(zhǎng)較快的細(xì)胞則可以多傳幾瓶，以具體細(xì)胞和經(jīng)驗(yàn)為準(zhǔn)。（懸浮細(xì)胞）用移液管輕輕吹打瓶壁，直接將溶液吸入離心管離心即可。